S0528 Lapatinib and Everolimus in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

DISEASE CHARACTERISTICS: Histologically or cytologically confirmed advanced solid tumor or non-Hodgkin's lymphoma for which no curative options exist Measurable or nonmeasurable disease Patients with brain metastases who require corticosteroids or anticonvulsants must be on a stable or decreasing dose of corticosteroids and seizure free for 30 days prior to study entry Patients with known brain metastases must have had brain irradiation (whole brain or gamma knife) No untreated (non-irradiated) brain metastases PATIENT CHARACTERISTICS: Zubrod performance status 0-2 Absolute neutrophil count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ SGOT or SGPT ≤ 2.5 times upper limit of normal (ULN) (5 times ULN if liver metastases are present) Bilirubin normal Creatinine normal OR creatinine clearance > 60 mL/min Cardiac ejection fraction normal by echocardiogram or MUGA Able to swallow enteral medications No feeding tubes No intractable nausea or vomiting No gastrointestinal (GI) tract disease resulting in an inability to take oral medication No current active hepatic or biliary disease with the exception of Gilbert's syndrome or asymptomatic gallstones No malabsorption syndrome No requirement for IV alimentation No uncontrolled inflammatory GI disease (e.g., Crohn's disease, ulcerative colitis) No history of allergic reactions attributed to compounds of similar chemical or biologic composition to lapatinib or everolimus, including other quinazoline compounds, such as gefitinib and erlotinib, or other rapamycins, such as sirolimus and temsirolimus No known HIV positivity No concurrent uncontrolled illness, including, but not limited to, any of the following: Ongoing or active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Myocardial infarction or cerebrovascular accident within the past 3 months Uncontrolled diarrhea Psychiatric illness or social situation that would preclude compliance with study requirements Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception Willing to undergo pharmacokinetic (PK) sampling and blood collection for PK and correlative studies (for patients enrolled in part II) PRIOR CONCURRENT THERAPY: See Disease Characteristics Recovered from prior therapy No prior lapatinib or everolimus No prior surgical procedures affecting absorption More than 14 days since prior major surgery, chemotherapy (42 days for nitrosoureas or mitomycin C), or radiotherapy More than 28 days since prior investigational agents At least 7 days since prior and no concurrent CYP3A4 inhibitors At least 14 days since prior and no concurrent CYP3A4 inducers At least 14 days since prior and no concurrent herbal or dietary supplements No concurrent chemotherapy, hormone therapy, radiotherapy, immunotherapy, live vaccines or any other anticancer therapy Concurrent luteinizing hormone-releasing hormone agonists allowed Concurrent bisphosphonates or epoetin alfa or its analogue allowed No concurrent gastric H2 blockers (e.g., cimetidine, ranitidine, nizatidine, famotidine) or proton pump inhibitors (e.g., omeprazole, esomeprazole, rabeprazole, pantoprazole, or lansoprazole) Antacids allowed provided they are not administered within 1 hour before and after lapatinib No concurrent glucocorticoids or immunosuppressants